Navigation Links
iVu Imaging Selects BancTec's Multi-Vendor Services Group as Exclusive Service Provider for Intelligent Volumetric Ultrasound Equipment
Date:3/31/2009

DALLAS, March 31 /PRNewswire/ -- BancTec, a global provider of advanced, high-volume, document and payment processing solutions and services, today announced that it has signed an exclusive service provider agreement with iVu Imaging, a medical device company focused on the early detection of cancer and other disease states. This agreement opens another new market for BancTec's growing Multi-Vendor Services Group.

"BancTec's Multi-Vendor Services Group has strong technical skills as well as a wide service footprint, two key factors in maintaining support on mission critical equipment that absolutely cannot be out of service for an extended period of time," said Russ Rogers, Vice President of Operations, iVu Imaging Corporation. "The combination of our proprietary imaging technology and BancTec's installation and support capabilities will help us meet the strong growth plan we have for the U.S. market."

"iVu Imaging has some truly innovative technology that will help many people improve their lives," said Terry Holash, Vice President, Multi-Vendor Services, BancTec. "We look forward to leveraging our national coverage model, as well as the ability of our technicians to work with unique equipment in the most demanding of environments, to help expand the use of iVu's imaging solutions across the country."

As the exclusive service provider for iVu, BancTec will deliver installation, maintenance and break/fix support. The imaging devices, which are capable of rapid 3D analysis of the human body for the earlier detection of numerous abnormal anatomical features and diseases, are typically sold to hospitals, health clinics and large doctor practices. The initial service agreement covers only the U.S. market.

About iVu Imaging Corporation

iVu Imaging Corporation develops and commercializes a proprietary core technology capable of rapid 3D analysis of the human body for the earlier
'/>"/>

SOURCE BancTec
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Brain imaging reveals breakdown of normal emotional processing
2. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
3. Fry Construction Selected for High-Profile Medical Imaging Project
4. Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel
5. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
6. Imaging Software Helps Track, Treat Injured Brains
7. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS)
10. Brain Imaging Expert Recruited to Study Autism at The Childrens Hospital of Philadelphia
11. Medical Imaging Revolutionizes Modern Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 1Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 2Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 3Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 4Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 5Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 6Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 7Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 8Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 9Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 10Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 11Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 12Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 13Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 14The Minnesota Nurses Association 3A School Nurses in Minnesota Celebrate 100 Years of Addressing Health Needs of School Children 60726 1The Minnesota Nurses Association 3A School Nurses in Minnesota Celebrate 100 Years of Addressing Health Needs of School Children 60726 2United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 60721 1United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 60721 2